RE:RE:Agreement for Tafasitamab and Pemigatinib in LATAM ...Snowballgrowth wrote: MrMugsy wrote: Does anyone have details on the agreement with Incyte?
Don't see any mention of dollars.
Don't see anything in SEDAR.
“In Knight, we have found a partner with an extensive track record of successful partnerships and strong distribution capabilities,” said Herv Hoppenot, Chief Executive Officer of Incyte. “We are eager to work together to expand access to tafasitamab and pemigatinib so that eligible patients in Latin America have access to these innovative medicines.”
Early sign of the benefits to working with Knight's ROW distribution network as per Incyte's comment?
But, can't tell how the deal is structured - when money changes hands.
https://docs.google.com/presentation/d/1qG1ComUfTrfSEZEPEcRJH0PXzJ6JCGBe/mobilepresent?slide=id.p1
They see $ 30-40 M revenues for LATAM
Thanks Snowball - nice summary - well said.
Nice to see the estimates - at least something to go on re. the new drugs ... once they get clearance in their geographies.